🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

393,17 USD

Máx. histórico

447,03

14 días

Split 2:1 del 22/11/1999

Caída desde máximo

-12,05%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-10,08%

Cierre anterior

437,23

Rango de hoy

391,17 – 410,03

Volumen hoy

6.589.429

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
24,44 (puede no estar actualizado)
Dividend yield
2,31% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 2 horas
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,53%
Fecha de pago Importe por participación
14/02/2019 1,4500 USD
15/11/2018 1,3200 USD
16/08/2018 1,3200 USD
16/05/2018 1,3200 USD
14/02/2018 1,3200 USD
16/11/2017 1,1500 USD
15/08/2017 1,1500 USD
15/05/2017 1,1500 USD
13/02/2017 1,1500 USD
14/11/2016 1,0000 USD
15/08/2016 1,0000 USD
13/05/2016 1,0000 USD
11/02/2016 1,0000 USD
12/11/2015 0,7900 USD
13/08/2015 0,7900 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
28/03/2002 60,87 60,95 59,57 59,68 -1,92% 2,27% 8.894.500
27/03/2002 60,30 61,39 60,11 60,85 +0,36% 2,12% 7.905.300
26/03/2002 60,23 60,98 60,05 60,63 +0,41% 1,54% 8.174.300
25/03/2002 61,95 61,98 60,35 60,38 -2,30% 2,63% 8.289.900
22/03/2002 61,81 62,48 61,29 61,80 -0,71% 1,93% 8.647.600
21/03/2002 61,08 62,25 60,60 62,24 +1,93% 2,70% 8.088.300
20/03/2002 61,99 62,25 61,06 61,06 -2,01% 1,92% 8.202.700
19/03/2002 62,55 62,94 61,86 62,31 -0,27% 1,73% 7.892.200
18/03/2002 61,79 62,62 61,60 62,48 +1,74% 1,65% 10.299.700
15/03/2002 60,11 61,47 60,00 61,41 +1,93% 2,45% 9.986.400
14/03/2002 59,75 60,98 59,74 60,25 +0,65% 2,08% 8.174.100
13/03/2002 60,09 60,49 59,07 59,86 +0,45% 2,36% 8.094.000
12/03/2002 58,92 59,70 58,50 59,59 +0,32% 2,04% 5.797.400
11/03/2002 59,42 59,87 58,91 59,40 -0,54% 1,62% 8.292.600
08/03/2002 60,24 60,25 58,73 59,72 -0,13% 2,52% 8.827.700
07/03/2002 59,97 60,59 59,21 59,80 -1,30% 2,30% 9.259.100
06/03/2002 59,19 60,61 58,90 60,59 +2,80% 2,89% 12.320.100
05/03/2002 59,44 60,25 58,52 58,94 -1,57% 2,91% 8.645.400
04/03/2002 59,00 59,90 58,89 59,88 +2,31% 1,71% 13.094.400
01/03/2002 58,17 58,70 57,01 58,53 +0,95% 2,91% 9.436.000
28/02/2002 58,17 59,03 57,88 57,98 +0,19% 1,98% 9.439.600
27/02/2002 59,19 59,45 57,50 57,87 -1,28% 3,29% 10.489.900
26/02/2002 58,99 59,25 57,92 58,62 -0,59% 2,25% 7.985.200
25/02/2002 57,56 59,00 57,37 58,97 +2,47% 2,83% 10.041.800
22/02/2002 56,78 57,75 56,20 57,55 -0,07% 2,73% 22.726.500
21/02/2002 58,44 59,95 57,53 57,59 -2,31% 4,14% 13.086.400
20/02/2002 57,68 58,96 57,10 58,95 +3,60% 3,22% 9.055.500
19/02/2002 57,80 57,95 56,65 56,90 -2,22% 2,25% 7.038.500
15/02/2002 57,91 58,80 56,80 58,19 +0,33% 3,45% 11.526.800
14/02/2002 58,73 59,80 57,47 58,00 -1,56% 3,97% 8.977.000